Tobramycin Inhalant Product

ApprovedSmall molecule

SShanghai Pulmonary Hospital, Shanghai, China

Tobramycin Inhalant Product is one of 36 small molecule programs targeting Bronchiectasis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BronchiectasisActive, not recruiting

BronchiectasisApproved

Active, not recruiting

Competition

Competitive Landscape

76 competitors in Bronchiectasis

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

1 2

Tobrex

VViatris Specialty LLC

Approved

2 3

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 4

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

1 5

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 6

Foradil

Qvar

Osmitrol

BB. Braun Medical Inc.

Phase 3

1 9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 10

Daliresp

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bronchiectasis2 trials

Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa

Unknown status·GGuangzhou Institute of Respiratory Disease·Phase 3·NCT03715322·350 enrolled

Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 4·NCT06093191·364 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tobramycin Inhalant Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tobramycin Inhalant Product compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tobramycin Inhalant Product. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pulmonary Hospital, Shanghai, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SShanghai Pulmonary Hospital, Shanghai, China

Tobramycin Inhalant Product

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bronchiectasis2 trials

References

Drug Info

Quick Facts

Related News